ArticleACS omega2026
Structure-Biofunction Relationships in Nanoparticle-Reinforced PVA/Alginate Hydrogels for Infection-Controlled Tissue-Contact Applications.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly-(vinyl alcohol)/sodium alginate (PVA/SA) hydrogels are promising tissue-contact biomaterials; however, the comparative effects of different reinforcing nanoparticles within the same polymer matrix remain insufficiently clarified. This study aimed to compare the structural and biological performance of PVA/SA hydrogel scaffolds reinforced with zinc oxide nanoparticles (ZnONPs), hydroxyapatite (HAp), and graphene oxide nanosheets (GONs) under identical preparation conditions. PVA/SA-based hydrogels were prepared using freeze-thaw processing and evaluated by electron microscopy, EDXS, FT-IR, and Raman spectroscopy. Their swelling behavior, in vitro mass loss in PBS, antibacterial activity, L929 fibroblast cytocompatibility, hemolytic activity, and blood clotting index (BCI) were also examined. The maximum swelling ratios were 3.70 for PVA/SA, 2.46 for PVA/SA/ZnONPs, 3.39 for PVA/SA/HAp, and 3.20 for PVA/SA/GONs. After 28 days, mass loss reached 13.1% for PVA/SA, 15.9% for PVA/SA/ZnONPs, 10.5% for PVA/SA/HAp, and 10.1% for PVA/SA/GONs. The MTT assay showed acceptable cytocompatibility in all groups, with L929 cell viability of 91.74 ± 3.49% for PVA/SA, 84.35 ± 2.68% for PVA/SA/ZnONPs, 95.28 ± 2.28% for PVA/SA/HAp, and 78.55 ± 6.15% for PVA/SA/GONs after 48 h. ZnO produced the most pronounced antibacterial effect, although the activity was moderate in absolute terms, reducing
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.